Genome editing has advanced at a rapid pace with promising results for treating genetic conditions-but there is always room for improvement.

Researchers have developed engineered human microglia that detect disease-related brain changes and release therapeutic ...

CRISPR and CRISPR-Associated Gene Market Set to Surge to $20 Billion by 2035, Fueled by Technological Breakthroughs and Biotech Investments The global CRISPR and CRISPR-Associated Gene Market Size is ...

Fintel reports that on April 21, 2025, Wolfe Research upgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from ...

Chinese biotech HuidaGene reports early success with first CRISPR brain treatment in 9-year-old with MECP2 duplication ...

Shares of Intellia Therapeutics (NASDAQ:NTLA) were up over 10% on Monday, after Wolfe Research upgraded the company to Outperform from Peer Perform.

As previously reported, Wolfe Research analyst Andy Chen upgraded Intellia Therapeutics (NTLA) to Outperform from Peer Perform with a $21 price ...

Wolfe Research upgraded Intellia Therapeutics (NTLA) to Outperform from Peer Perform with a $21 price target Stay Ahead of the Market: ...

Latest study leverages new constructs for nuclear localization signal (NLS) sequences to improve editing efficiency in human ...

The North America CRISPR gene editing market is poised for substantial growth, with projections indicating a robust annual expansion of 24.4% throughout the forecast period. By 2031, it is anticipated ...

The CRISPR gene editing technology has revolutionized the field of molecular biology, offering unprecedented precision and efficiency in genetic manipulation. With its vast potential in various ...